StockIQpro
NASDAQ:FHTX

Foghorn Therapeutics Inc.

Track all markets on TradingView
Track all markets on TradingView

Foghorn Therapeutics Inc.'s revenue grew 36.8% in fiscal 2025 to $30.9M while operating margin rose to −279.5%, its highest in 6 years. Free cash flow was −$86.1M, −278.7% of revenue, and the diluted share count rose 14.7%.Summary generated from Foghorn Therapeutics Inc.'s SEC filings. Latest annual report filed Mar 11, 2026.

Key statistics

Fiscal 2025 from SEC filings. Methodology
Revenue (FY25)$30.9M
Revenue growth+36.8%
Revenue, 5-yr CAGR+135.1%
Gross marginn/a
Operating margin−279.5%
Net margin−240.3%
ROICn/a
Return on equityn/a
Debt / equityn/a
Free cash flow−$86.1M
FCF margin−278.7%
Share count change+14.7%

Financials

Fiscal years, $M
Item20212022202320242025
Revenue119342331
Operating income−101−117−108−103−86
Net income−101−109−98−87−74
Free cash flow−54192−119−101−86

Recent filings

From SEC EDGAR

Peers

Pharmaceutical preparations